Should there be patient and public involvement in HTAs?

Both patients and the public have to be regularly informed about what the use and procedures of HTA are and how it fits in making the healthcare system more efficient for them.  They should have the same right as other stakeholders and actors of the process in the evaluation of new therapies, which should not just be based on economics but also on other, including social values.  Patient and public involvement needs to be clear, transparent and become a key structural element of any evaluation of innovative therapies.